NEC Corporation, a leader in IT and network technologies, and VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the companies have signed a strategic clinical trial collaboration agreement and an equity investment agreement to develop novel personalized neoantigen cancer vaccines. Under the terms of the collaboration agreement, which is non-exclusive to both parties, NEC will provide funding for a Phase I clinical trial. NEC and VAXIMM will co-develop personalized cancer vaccines using NEC's cutting-edge artificial intelligence (AI) technology, which is utilized in its Neoantigen Prediction System, and VAXIMM's proprietary T-cell immunotherapy technology. The vaccines are planned to be evaluated in a Phase I clinical trial in various solid tumors. VAXIMM will be responsible for conducting the clinical trial, which is expected to be initiated in 2020.

Tuesday's best early Black Friday deals on Amazon are on some of the most popular holiday gifts. If you make a purchase by clicking one of our links, we may earn a small share of the revenue. However, our picks and opinions are independent from USA Today's newsroom and any business incentives. Coming back from a long weekend is always hard, especially one that's so close to the holidays, like Veteran's Day. If you're just settling back into the office, chances are you could use a few distractions, and lucky for you, we've got five of them--specifically in the form of these great deals you can snag on Amazon.

Marketers in 2019 will find it hard to be successful without understanding the cultural transformation that's happening in this country. Between 2012 and 2017, the US multicultural population – Hispanics, African Americans, and Asian Americans – grew to 11.7 million people. Notably, these groups are younger and growing at a faster rate than their White counterparts. This makes multicultural marketing an essential component of all advertising campaigns. Yet, even the most seasoned and "culturally woke" brands can have trouble navigating this cultural transformation and shifts in consumer behavior.

Bipartisanship in modern politics can seem kind of like an unbelievable, mythical creature. But in recent months, as Congress considered regulation of one of the most controversial topics it faces -- how, when, or if to use facial recognition -- we've gotten glimpses of a political unicorn. In two House Oversight and Reform committee hearings last summer, some of the most prominent Republicans and Democrats in the United States Congress joined together in calls for legislative reform. Proponents of regulation ranged from Rep. Alexandria Ocasio-Cortez (D-NY) to Rep. Jim Jordan (R-OH), a frequent Trump supporter on cable news. On Friday, Jordan was also appointed to the House Intelligence Committee to confront witnesses in public presidential impeachment hearings that begin this week.

Woodside and IBM will work together to re-imagine the way work is done using next-generation technologies such as artificial intelligence (AI) and quantum computing to help Woodside realize its vision of an "intelligent plant." Announced today at IBM's Cloud Innovation Exchange in Sydney by Woodside CEO Peter Coleman and IBM Chairman, President and CEO Ginni Rometty, the collaboration will include Woodside becoming a member of the MIT-IBM Watson AI Lab, which is a collaborative industrial-academic laboratory focused on advancing fundamental AI research. Woodside will also join the IBM Q Network, making it the first commercial organization in Australia to join IBM's quantum computing network. Woodside and IBM will use quantum computing to conduct deep computational simulations across the value chain of Woodside's business. During the past five years Woodside and IBM have worked together to implement cognitive solutions, enabling advances in health and safety, planning and operations, and project engineering.

Most large banks in the US are pursuing AI fairly assiduously, but JPMorgan Chase stands out for the depth of its commitment to the technology, the breadth of projects it has adopted, and the focus on driving actual business change from its AI initiatives. The Bank, the largest in the US and 6th largest in the world in terms of total assets, has AI projects or production applications in all the usual areas of banking: risk, fraud prevention, marketing, investment banking, wealth management advice, trading, back office automation, and customer engagement (particularly in the corporate banking area thus far). But JPMorgan Chase distinguishes itself from other banking firms in its level of investment, its hiring of AI academic stars, and its coordinated approach to the management of AI and analytics. JPMorgan Chase spends $11 billion a year on technology, and about half of that amount is devoted to research on new and emerging technologies. Its research investments cover a wide variety of domains, including investments in AI startups and AI-based hedge funds.

New York, After looking at standard ECG tests, Artificial Intelligence (AI) can help identify patients most likely to die of any medical cause within a year, claim researchers. To reach this conclusion, researchers from Geisinger Health System in Pennsylvania analyzed the results of 1.77 million ECGs and other records from almost 400,000 patients. The team used this data to compare machine learning-based models that either directly analyzed the raw ECG signals or relied on aggregated human-derived measures (standard ECG features typically recorded by a cardiologist) and commonly diagnosed disease patterns. The neural network model that directly analyzed the ECG signals was found to be superior for predicting one-year risk of death. Surprisingly, the neural network was able to accurately predict risk of death even in patients deemed by a physician to have a normal ECG.

In 2002, Target hired statistician Andrew Pole. His job was to use predictive analytics -- a form of statistics that makes predictions by observing data trends -- to help the retail giant market certain products to certain groups of people. Along those lines, Pole's first task was to identify pregnant women -- specifically women in their second trimester. As Target's marketing team explained to him, new parents are extremely valuable customers whose brand loyalty tends to change when they have kids because they purchase things they probably weren't purchasing before -- like diapers, formula, baby clothes, etc. New parents also tend to be physically exhausted and therefore more prone to do all of their shopping at one place.

Artificial intelligence can examine electrocardiogram (ECG) test results, a common medical test, to pinpoint patients at higher risk of developing a potentially dangerous irregular heartbeat (arrhythmia) or of dying within the next year, according to two preliminary studies to be presented at the American Heart Association's Scientific Sessions 2019--November 16-18 in Philadelphia. Researchers used more than 2 million ECG results from more than three decades of archived medical records in Pennsylvania/New Jersey's Geisinger Health System to train deep neural networks--advanced, multi-layered computational structures. Both studies, from the same group of researchers, are among the first to use artificial intelligence to predict future events from an ECG rather than to detect current health problems, the scientists noted. "This is exciting and provides more evidence that we are on the verge of a revolution in medicine where computers will be working alongside physicians to improve patient care," said Brandon Fornwalt, M.D., Ph.D., senior author on both studies and associate professor and chair of the Department of Imaging Science and Innovation at Geisinger in Danville, Pennsylvania. Researchers speculated that a deep learning model could predict irregular heart rhythms, known as atrial fibrillation (AF), before it develops.

Russian Direct Investment Fund (RDIF) is considering investments in the Botkin.AI platform developed by Intellogic LLC and the OSA Hybrid Platform, one of Russia's leading companies in RetailTech, the Fund said in a statement on Saturday. Botkin.AI, a high-tech platform for medical image analysis, is used for diagnostics and disease risk assessment. "By supporting the Botkin.AI platform, RDIF and its partners seek to provide medical centers with additional tools for effective, efficient and timely diagnosis. AI enables doctors to choose the right treatment tactics and, if necessary, consult with colleagues using the platform's capabilities. We see significant opportunities for the expansion of Botkin.AI internationally and are committed to helping the platform enter the global healthcare market," RDIF Chief Executive Officer Kirill Dmitriev was quoted as saying.